Skip to content
value.today

Quoin Pharmaceuticals Ltd.

Total raised
$4 M
1 round on record
Latest round
$4 M
Sep 2017
First round on record
Sep 2017
Today
Went public
See the company page

Quoin Pharmaceuticals Ltd. is listed today as Quoin Pharmaceuticals, Ltd.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Quoin Pharmaceuticals Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$50 MPrivate placement after listing$50 to $250 million

Quoin Pharmaceuticals Ltd.: Private sale, Aug 2026

Investors in this round

33 investors had bought by the notice of Sep 10, 2026: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,039
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Israel

People named in the notice

  • Denise Bridget Carter · Executive Officer, Director
  • Michael Myers · Executive Officer, Director
  • Sally Bridget Lawlor · Executive Officer
  • Dennis Bridget Langer · Director
  • James Bridget Culverwell · Director
  • Joseph Bridget Cooper · Director
  • Michael Bridget Sember · Director
  • Natalie Bridget Leong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 000122225) · New York, New YorkSold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US
  • Lake Street Capital Markets, LLC (CRD 000164447) · Minneapolis, MinnesotaSold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US
  • Leerink Partners LLC (CRD 000039011) · New York, New YorkSold in CA, CT, DE, FL, MD, NC, NJ, NY, OR, and outside the US

Remarks in the notice

  • On fees: “Consists of fees due to placement agents equal in aggregate to 6.0% of gross offering proceeds, assuming cash exercise of all warrants issued. Lead placement agent also entitled to reimbursement for reasonable out-of-pocket expenses, not included here.”
  • On the amounts: “The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers.”

Signed by Sally Lawlor, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2026. Read the notice at the SEC.

equity, optionsSEC
Oct 2025$105 MPrivate placement after listing$50 to $250 million

Quoin Pharmaceuticals Ltd.: Private sale, Oct 2025

Investors in this round

27 investors had bought by the notice of Oct 23, 2025: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$105 M of $105 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,227,995
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Israel

People named in the notice

  • Denise Bridget Carter · Executive Officer, Director
  • Michael Myers · Executive Officer, Director
  • Sally Bridget Lawlor · Executive Officer
  • Dennis Bridget Langer · Director
  • James Bridget Culverwell · Director
  • Joseph Bridget Cooper · Director
  • Michael Bridget Sember · Director
  • Natalie Bridget Leong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Maxim Group LLC (CRD 000120708) · New York, New YorkSold in CA, CT, DE, KY, MD, NJ, NV, NY, TX, and outside the US

Remarks in the notice

  • On fees: “Estimated commissions and fees paid at closing include cash fee of 7% of aggregate gross proceeds of private placement (except no cash fee paid for securities purchased by a Company director) and up to $75,000 for legal and other out-of-pocket expenses.”
  • On the amounts: “The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement.”
  • On the use of proceeds: “While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers”

Signed by Dr. Michael Myers, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 23, 2025. Read the notice at the SEC.

equity, optionsSEC
Jan 2018$4 MPrivate placement after listing$2 to $10 million

Quoin Pharmaceuticals Ltd.: Private sale, Jan 2018

Investors in this round

3 investors had bought by the notice of Feb 9, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$280,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Eyal Nuriel Leibovitz · Executive Officer
  • Shai Nuriel Yarkoni · Executive Officer, Director
  • Abraham Nuriel Nahmias · Director
  • David Nuriel Braun · Director
  • Kasbian Nuriel Chirich · Director
  • Michael Nuriel Berelowitz · Director
  • Ruhama Nuriel Avraham · Director
  • Ruth Nuriel Ben Yakar · Director
  • Yuval Nuriel Berman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in IL, NJ

Remarks in the notice

  • On fees: “H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $25,000 and warrants to purchase 24,242 ADSs exercisable at $10.31 per ADS immediately for a period of one year from the date of filing an effective registration statement.”
  • On the amounts: “The warrants and shares underlying the warrants were issued in connection with an offering of (i) 484,848 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants to purchase up to 266,667 ADSs.”
  • On the use of proceeds: “Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers”

Signed by Eyal Leibovitz, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 9, 2018. Read the notice at the SEC.

optionsSEC
Sep 2017$4 MNo. 1$2 to $10 million

Quoin Pharmaceuticals Ltd.: Raise no. 1, Sep 2017

Investors in this round

18 investors had bought by the notice of Sep 19, 2017: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
$84,963
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Israel

People named in the notice

  • Eyal Nuriel Leibovitz · Executive Officer
  • Shai Nuriel Yarkoni · Executive Officer, Director
  • Abraham Nuriel Nahmias · Director
  • David Nuriel Grossman · Director
  • Kasbian Nuriel Chirich · Director
  • Michael Nuriel Berelowitz · Director
  • Ruth Nuriel Ben Yakar · Director
  • Yuval Nuriel Berman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, CT, NY, and outside the US

Remarks in the notice

  • On fees: “H.C. Wainwright, LLC is also entitled to non-accountable expense reimbursement of $15,000 and up to $30,000 for certain expenses. H.C. Wainwright is entitled to warrants to purchase an aggregate of 7,492 ADSs exercisable at $10.125 per ADS for five years.”
  • On the amounts: “The warrants and shares underlying the warrants, the subject matter of this Form D were issued in connection with an offering of (i) 531,136 ADSs issued in a registered direct offering, which are not subject to this Form D, and (ii) unregistered warrants”
  • On the use of proceeds: “Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers”

Signed by Eyal Leibovitz, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 19, 2017. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Quoin Pharmaceuticals Ltd. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2026

That is all the official record says: Quoin Pharmaceuticals Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Quoin Pharmaceuticals Ltd. are on record.

Investors#

No investor of Quoin Pharmaceuticals Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 18 investors.

Largest shareholders today

Institutions holding Quoin Pharmaceuticals, Ltd. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Quoin Pharmaceuticals Ltd.
NameRoleNamed in
Denise Bridget CarterExecutive officerSep 2026
Michael MyersExecutive officerSep 2026
Sally Bridget LawlorExecutive officerSep 2026
Eyal Nuriel LeibovitzExecutive officerFeb 2018
Shai Nuriel YarkoniExecutive officerFeb 2018
Denise Bridget CarterDirectorSep 2026
Dennis Bridget LangerDirectorSep 2026
James Bridget CulverwellDirectorSep 2026
Joseph Bridget CooperDirectorSep 2026
Michael Bridget SemberDirectorSep 2026
Michael MyersDirectorSep 2026
Natalie Bridget LeongDirectorSep 2026
Abraham Nuriel NahmiasDirectorFeb 2018
David Nuriel BraunDirectorFeb 2018
Kasbian Nuriel ChirichDirectorFeb 2018
Michael Nuriel BerelowitzDirectorFeb 2018
Ruhama Nuriel AvrahamDirectorFeb 2018
Ruth Nuriel Ben YakarDirectorFeb 2018
Shai Nuriel YarkoniDirectorFeb 2018
Yuval Nuriel BermanDirectorFeb 2018
David Nuriel GrossmanDirectorSep 2017

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.